{"organizations": [], "uuid": "e404b3b3ac98efdd922ea73340a1625c6889c2e7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-deciphera-pharma-expects-to-start/brief-deciphera-pharma-expects-to-start-late-stage-study-in-patients-with-gastric-tract-tumors-in-second-half-of-2018-idUSFWN1RU0YQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Deciphera Pharma Expects To Start Late-Stage Study In Patients With Gastric Tract Tumors In Second Half Of 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.227, "site_type": "news", "published": "2018-04-17T21:18:00.000+03:00", "replies_count": 0, "uuid": "e404b3b3ac98efdd922ea73340a1625c6889c2e7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-deciphera-pharma-expects-to-start/brief-deciphera-pharma-expects-to-start-late-stage-study-in-patients-with-gastric-tract-tumors-in-second-half-of-2018-idUSFWN1RU0YQ", "ord_in_thread": 0, "title": "BRIEF-Deciphera Pharma Expects To Start Late-Stage Study In Patients With Gastric Tract Tumors In Second Half Of 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "deciphera pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - Deciphera Pharmaceuticals Inc:\n* PRECLINICAL DATA DEMONSTRATE THAT DECIPHERA PHARMACEUTICALS’ DCC-2618 EXHIBITS BROADER INHIBITION PROFILE AGAINST PRIMARY AND SECONDARY DRUG-RESISTANT MUTATIONS IN GASTROINTESTINAL STROMAL TUMORS (GIST) COMPARED TO APPROVED AND INVESTIGATIONAL AGENTS\n* DECIPHERA PHARMACEUTICALS - DCC-2618 DEMONSTRATED BROADEST PROFILE OF INHIBITION OF PRIMARY AND SECONDARY KIT MUTATIONS AND PRIMARY PDGFRΑ MUTATIONS\n* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 3 REGISTRATION STUDY IN 2(ND) LINE GIST PATIENTS IN SECOND HALF OF 2018\n* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO REPORT TOP-LINE DATA FROM ONGOING INVICTUS STUDY IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T21:18:00.000+03:00", "crawled": "2018-04-18T17:58:28.012+03:00", "highlightTitle": ""}